Toxicity of infliximab in the course of treatment of Crohn’s disease

Author： Bratcher Jason M   Korelitz Burton I  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.1, 2006-01, pp. : 9-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease

By Peter D. Han   Russell D. Cohen  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite

Economic Implications of Biological Therapies for Crohn’s Disease: Review of Infliximab

By Bodger Keith  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite

TNF- antagonists for the treatment of Crohn’s disease

By Kam L.Y.   Targan S.R.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 615-622

Informa Healthcare

Access to resources Recommend Favorite

Recent developments in the pharmacological treatment of Crohn’s disease

By Srinivasan Radhika   Lichtenstein Gary R  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 4, 2004-04 ,pp. : 373-391

Informa Healthcare

Access to resources Recommend Favorite

Severe myalgia associated with mesalazine treatment in a child with Crohn’s disease

By Peršić Mladen   Palčevski Goran   Slavić Irena   Vlahović-Palčevski Vera  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 3, 2007-03 ,pp. : 315-317

Springer Publishing Company

Access to resources Recommend Favorite